Inovio Pharmaceuticals, Inc. (INO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jacqueline E. Shea Ph.D. | CEO, President & Director | 1.13M | -- | 1966 |
| Mr. Peter D. Kies | Chief Financial Officer | 810.2k | -- | 1963 |
| Dr. Laurent M. Humeau Ph.D. | Chief Scientific Officer | 794.08k | -- | 1967 |
| Thomas Hong | Manager of Investor Relations | -- | -- | -- |
| Mr. Robert L. Crotty J.D. | General Counsel & Chief Compliance Officer | -- | -- | 1974 |
| Mr. E. J. Brandreth MBA | Senior Vice President of Quality Assurance | -- | -- | -- |
| Dr. Jeffrey Skolnik | Senior Vice President of Clinical Development | -- | -- | -- |
| Mr. Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing & Clinical Supply Management | -- | -- | -- |
| Mr. Stephen Kemmerrer M.B.A., P.E. | Senior Vice President of Engineering Development | -- | -- | -- |
| Mr. Shawn D. Bridy M.A., M.B.A. | Senior Vice President of Business Development | -- | -- | -- |
Inovio Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 122
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Corporate Governance
Recent Events
- Apr 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 15, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 11, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 06, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 29, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing